Share on StockTwits

Cowen and Company boosted their price objective on shares of Gilead Sciences (NASDAQ:GILD) from $95.00 to $105.00 in a research note issued on Friday. The firm currently has an “outperform” rating on the stock. Cowen and Company’s target price suggests a potential upside of 8.97% from the stock’s previous close.

Shares of Gilead Sciences (NASDAQ:GILD) traded up 3.25% on Friday, hitting $99.49. The stock had a trading volume of 19,672,960 shares. Gilead Sciences has a 1-year low of $56.25 and a 1-year high of $96.37. The stock has a 50-day moving average of $89.64 and a 200-day moving average of $81.09. The company has a market cap of $150.4 billion and a price-to-earnings ratio of 21.83.

Gilead Sciences (NASDAQ:GILD) last released its earnings data on Wednesday, July 23rd. The company reported $2.36 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.73 by $0.63. The company had revenue of $6.53 billion for the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter in the previous year, the company posted $0.50 earnings per share. The company’s revenue for the quarter was up 136.1% on a year-over-year basis. Analysts expect that Gilead Sciences will post $8.02 EPS for the current fiscal year.

A number of other analysts have also recently weighed in on GILD. Analysts at RBC Capital initiated coverage on shares of Gilead Sciences in a research note on Friday. They set an “outperform” rating on the stock. Separately, analysts at FBR Capital Markets initiated coverage on shares of Gilead Sciences in a research note on Thursday. They set an “outperform” rating and a $125.00 price target on the stock. Finally, analysts at Argus initiated coverage on shares of Gilead Sciences in a research note on Monday. They set a “buy” rating and a $110.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and twenty-one have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $105.05.

In other Gilead Sciences news, Director Richard James Whitley sold 5,000 shares of the company’s stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $91.00, for a total value of $455,000.00. The sale was disclosed in a filing with the SEC, which is available at this link.

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.